Concepts and Strategies for the Site Specific Delivery of Nanocarrier Based Delivery Systems for Treating Hepatocellular Carcinoma

ISSN: 1875-5704 (Online)
ISSN: 1567-2018 (Print)

Volume 12, 6 Issues, 2015

Download PDF Flyer

Current Drug Delivery

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Istvan Toth
School of Pharmacy,University of Queensland
Brisbane, 4072

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 1.478

Concepts and Strategies for the Site Specific Delivery of Nanocarrier Based Delivery Systems for Treating Hepatocellular Carcinoma

Current Drug Delivery, Volume 10 (E-pub ahead of print)

Author(s): Pooja Sharma, Archana Pandita and RSR Murthy.

Affiliation: Nanomedicine Research Centre, I.S.F College of Pharmacy, Moga, Punjab- 142001


Hepatocellular carcinoma (HCC) is most common lethal malignancy worldwide. About 80% of liver cancer cases are attributed to the combined effects of Hepatitis B and C virus infections. The factors affecting development of HCC include cirrhosis and histological markers of increased liver cell proliferation, environmental, dietary and lifestyle of the person. Treatment options depend on the presence or absence of cirrhosis, number and size of tumors, and degree of hepatic deterioration. The primary option for some of the patients include hepatic resectioning, locoregional ablation, liver transplantation, ultrasound-guided tumor injection with absolute ethanol or tumor thermoablation with radiofrequency. Most common drugs like sorafenib, doxorubicin and daunorubicin have been used widely for treatment of HCC. A number of novel formulations like polymeric nanoparticles, nanocapsules, liposomes, nanoemulsions, microsphere, hydrogels, dendrimers, polymeric micelles has been reported for the treatment of HCC. The advantages of novel drug delivery systems (NDDS) is based on the ability to modify the bio-distribution, pharmacokinetics and pharmacological activity, prolonged efficacy and duration of drug activity, improved patient compliance, drug targeting to the site of action, enhancement of solubility, bioavailability, protection from toxicity, enhancement of stability. The carriers for liver specific drug delivery include liver-specific asialoglycoprotein receptor on mammalian hepatocytes. The natural ligand i.e. asialofeutin, or synthetic ligands with galactosylated or lactosylated polymers have been developed for significant targeting to the liver

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 10
First Page: 1
Page Count: 1
DOI: 10.2174/1567201810666131124140259
Controlled Release

Related Journals

Webmaster Contact: Copyright © 2015 Bentham Science